Celgene to Acquire Receptos for $7.2 Billion in Continuation of Buying Spree

7/15/2015 Biotech manufacturer Celgene is making an earnest push to become one of the industry’s leaders following a wave of transactions aimed at increasing long-term sustainability. Celgene’s current success is largely based on the popularity of its breakthrough cancer drug, Revlimid; however Celgene is attempting to set itself up for future growth when Revlimid’s patent


FDA to Review Birth Control Device Essure due to Side Effect Concern

The U.S. Food and Drug Administration (FDA) is joining famous environmental and consumer activist Erin Brockovich in its skepticism of Bayer’s popular birth control device, Essure. Bayer claims that the coil-like device is the only non-surgical permanent form of birth control on the market. The FDA announced last month that it will be conducting a



Novartis Faces up to $3.3 Billion in Damages from Whistleblower Kickback Suit

7/2/2015 In what may be the largest whistleblower lawsuit ever, the Justice Department, along with 11 states, are accusing Swiss pharmaceutical titan, Novartis, of running a massive kickback scheme through the U.S. Medicare and Medicaid programs. Specifically, the U.S. is accusing the drugmaker of referring patients to a handful of specialty pharmacies who sent in



HHS Reports identify Rampant Medicare Part D Fraud

6/24/2015 Two reports released on Tuesday highlight the persistence of Medicare fraud, especially involving the Part D prescription drug program. The reports follow the largest Healthcare Fraud takedown in history last week, as officials charged 46 doctors and pharmacy owners, as well as nearly 200 others for Medicare fraud. This includes the arrest of 44


House Will Vote to Repeal Key Obamacare Measures

6/18/2015 The House of Representatives will vote Thursday to repeal two controversial provisions to the Affordable Care Act (ACA), better known as Obamacare. Amidst a considerable degree of bipartisan support, Ways and Means Committee chairman, Paul Ryan (R-WI) successfully advanced measures to a vote earlier this month to cut the unpopular 2.3 percent tax on


FDA to consider new Class of Cholesterol Drugs

6/9/2015 A new class of cholesterol drugs will undergo a preliminary review this week from a Food and Drug Administration (FDA) advisory panel. The drugs, Amgen’s Evolocumab and Alirocumab from Sanofi SA and partner, Regeneron Pharmaceuticals, block a protein called PCSK9, which can prevent the liver from eliminating bad cholesterol. Early studies show the drugs



How long until Power Morcellators are Banned?

5/29/2015 Despite the ongoing FBI investigation of Johnson & Johnson’s manufacturing division, Ethicon, and a strong Food and Drug Administration (FDA) warning issued last year, power morcellators are still legal. The device grinds up tissue mass, and is then removed through a series of small incisions. The device, which is used to provide minimally invasive